Back to results
US 8,278,306 B2Granted
C-met protein kinase inhibitors
AssigneeVertex Pharmaceuticals Incorporated
InventorsJeremy Green, Jingrong Cao, Upul Keerthi Bandarage, Jon H. Come, Craig Marhefka
Life of this patent
Estimating the term…
Abstract
Described herein are compounds that are useful as ROCK inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including cardiovascular, inflammatory, neurological, or proliferative diseases or disorders.
Claims16
A compound having the formula:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is halogen —NR2, —OR, —SR, or a C1-4 alkyl;
- R2 is hydrogen or C1-3 aliphatic;
- each R3 is, independently, hydrogen or a C1-4 alkyl;
- X1 is N;
- T is a bond or a C1-C6 alkylidene chain, wherein up to two methylene units of T are optionally and independently replaced by —NR′—, —S—, —O—, —C(O)NR′—, —NR′C(O)—, —NR′C(O)O—, —S(O)2NR′—, —NR′S(O)2—, —NR′C(O)NR′—, —OC(O)NR′—, or —NR′S(O)2NR′—;
- each R5 is, independently, Ra or halogen;
- n is 1 to 3;
- each occurrence of Ra is, independently, hydrogen, an optionally substituted moiety selected from a C1-4 alkyl group, a C3-6 cycloalkyl group, a C1-4 haloalkyl group, or a heterocyclic ring selected from morpholino, piperidinyl, or piperazinyl;
- each optionally substituted group or ring is optionally substituted with 1-5 substituents independently selected from C1-4 alkyl, C3-6 cycloalkyl, C1-4 haloalkyl, halogen, or —OR″;
- each occurrence of R is, independently, hydrogen, a C1-4 alkyl group, a C3-6 cycloalkyl group, —(CH2)1-2Ph, —CH═CHPh, or a C1-4 haloalkyl group;
- each occurrence of R′ is, independently, hydrogen or a C1-4 alkyl group;
- and
- each occurrence of R″ is, independently, hydrogen or a C1-4 alkyl group.
11 more elements
A compound selected from
Dependencies are inferred from the claim text.